查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1909217

Dapagliflozin淨銷售預測與市場規模分析（2034 年）

Dapagliflozin Sales Forecast, and Market Size Analysis - 2034
出版日期: | 出版商: DelveInsight | 英文 30 Pages | 商品交期: 2-10個工作天內

價格

推動Dapagliflozin淨成長的關鍵因素

1. 擴大市場佔有率並增加新患者數量

  • 由於Dapagliflozin具有廣泛的心血管代謝作用，因此在糖尿病、心臟衰竭和慢性腎臟病(CKD) 領域繼續獲得市場佔有率。
  • 新患者數量的不斷成長，尤其是在傳統糖尿病領域之外的患者，支撐著處方箋和銷售量的穩定成長。
  • 醫生們的深刻理解和基於指南的採納，鞏固了其作為心臟病學、腎臟病學和內分泌學實踐中基石療法的地位。

2. 主要適應症的擴展

  • 2 型糖尿病 (T2DM)：Dapagliflozin是一種成熟的 SGLT2 抑制劑，永續提供持久的血糖控制以及體重和血壓方面的益處。
  • 心臟衰竭（HFrEF 和 HFpEF）：它正迅速成為糖尿病和非糖尿病患者心臟衰竭的標準治療方法，在減少住院和心血管死亡方面取得了良好的效果。
  • 慢性腎臟病（CKD）：已證實具有腎臟保護作用並能延緩疾病進展，因此在患有或未患有糖尿病的 CKD 患者中得到了更廣泛的應用。
  • 持續的研究和生命週期管理將探索更廣泛的心血管代謝和腎臟病應用，從而加強長期市場擴張。

3. 地理擴張

  • Dapagliflozin已在全球廣泛應用，在北美、歐洲和主要新興市場的應用率很高。
  • 由於糖尿病盛行率上升、心臟衰竭和慢性腎臟病診斷病例增加，以及獲得創新療法的機會改善，預計亞太地區和拉丁美洲將加速成長。
  • 策略定價、在地化生產和夥伴關係正在推動對成本敏感地區的市場進一步滲透。

4. 新適應症的核准

  • 達格列淨在糖尿病、心臟衰竭和慢性腎臟病(CKD) 領域獲得多項監管核准，顯著擴大了符合Dapagliflozin條件的患者群體。
  • 適應症擴展到糖尿病以外，使該藥物重新定位為多學科治療方法，增強了其與其他降血糖藥物的競爭力。
  • 這些核准使收入來源多元化，減少了對糖尿病市場的單一依賴，並提高了長期永續性。

5. 心腎領域銷售量強勁成長

  • 心臟衰竭和慢性腎臟病(CKD) 領域是主要促進因素，其持續的銷售量成長勢頭得益於優異的臨床結果和國際治療指南的採納。
  • 真實世界和長期追蹤數據進一步鞏固了循環系統和腎臟科醫師的信心，加速了新確診患者和高風險患者的採用。

6. 競爭差異化與市場趨勢

  • 每日一次口服給藥，且安全性良好，有助於提高用藥的便利性和長期依從性。
  • 除了血糖控制之外，Dapagliflozin還緩解疾病作用，這使它有別於傳統的抗糖尿病藥物。
  • 與更廣泛的醫療保健趨勢保持一致，例如心腎代謝綜合護理、早期療育和基於價值的護理模式，是持續採用的強大驅動力。
  • 真實世界數據 (RWE) 的累積正在增強多個市場支付方的接受度，並推動有利的報銷決策。

Dapagliflozin的最新趨勢

Dapagliflozin在心腎和代謝疾病的治療中持續發揮核心作用。最新的臨床分析和真實世界研究證實，達格列淨對各種心率輸出頻譜的心臟衰竭患者以及非糖尿病慢性腎臟病（CKD）患者均有益處，進一步增強了醫生對其的信心。持續的上市後證據和指南更新鞏固了其作為基礎治療而非輔助性治療的地位。此外，達格列淨持續被納入全球和區域臨床實踐指南，也支持其長期效用。同時，其生命週期管理策略著眼於在SGLT2抑制劑類藥物競爭日益激烈的背景下，維持其市場成長。

《Dapagliflozin淨銷售預測及市場規模分析（2034）》報告核准分析了達格列淨在七個主要國家（美國、四個歐盟國家（德國、法國、義大利和英國）、英國、法國和義大利）的市場情況，涵蓋了已獲批准的適應症（如重症血小板減少性疾病）以及潛在適應症（如新生兒修格蘭氏症候群、全身性紅斑性狼瘡血小板系統減少症、新生兒同種乾性狼瘡和本報告詳細描述了Dapagliflozin在上述七個主要國家（美國、四個歐盟國家（德國、法國、義大利和西班牙）、英國和日本）的現有使用情況、預期市場准入情況以及核准和潛在適應症的市場表現，研究週期為2020年至2034年。此外，報告還對Dapagliflozin在核准和潛在適應症中的應用進行了詳細描述。這份Dapagliflozin市場報告深入分析了達格列淨的研發及其他活動，包括銷售預測、作用機制、劑量和給藥途徑以及監管里程碑。此外，報告還提供了Dapagliflozin的Dapagliflozin和當前市場表現、未來市場評估（包括對七個主要國家已通過核准和潛在適應症的Dapagliflozin市場預測分析）、SWOT分析、分析師觀點、市場競爭對手的全面概述以及針對每種適應症的其他新興治療方法的概述。該報告還對Dapagliflozin的銷售預測以及市場促進因素進行了分析。

Dapagliflozin藥物概述

Dapagliflozin（商品名： Farxiga ）是一種選擇性鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑，主要用於治療第2型糖尿病、心臟衰竭和慢性腎臟病。它透過抑制腎臟近端小管的SGLT2，減少葡萄糖的重吸收，從而促進糖尿、熱量消耗，並以不依賴胰島素的方式降低血糖值。它還能誘導鈉排泄，從而降低血壓並帶來輕微的體重減輕。達格列核准每日一次口服（5-10毫克），對多種患者族群均具有心臟保護和腎臟保護作用，可減少重大心血管事件、心臟衰竭住院和腎臟疾病進展。本報告提供有關Dapagliflozin的銷售、成長障礙和促進因素、使用情況以及多種適應症的核准情況的資訊。

Dapagliflozin目前處於治療第 2 型糖尿病患者的 III 期臨床開發階段 (NCT04634500)。

Dapagliflozin市場報告覆蓋範圍

本報告深入分析了以下內容：

  • Dapagliflozin淨的全面產品概述，包括其作用機制（MoA）、產品說明、劑量和給藥方法，以及針對核准適應症（如重症肌無力）和潛在適應症（如胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病症、修格蘭氏症候群和全身性紅斑性狼瘡）的研究和開發活動。
  • Dapagliflozin市場報告提供了有關監管里程碑和其他開發活動的詳細資訊。
  • 該報告還重點介紹了Dapagliflozin在美國、歐洲和日本已通過核准和潛在適應症的成本估算和區域差異、已報告和估計的銷售額以及研發活動。
  • Dapagliflozin市場報告還涵蓋專利資訊、學名藥藥上市及其對降低成本的影響。
  • 這份Dapagliflozin市場報告提供了截至 2034 年Dapagliflozin在已通過核准和潛在適應症中的當前和預測銷售額。
  • 此外，也全面介紹了每種適應症中新興的後期治療方法。
  • 這份Dapagliflozin市場報告還包含 SWOT 分析，以及分析師對Dapagliflozin在已通過核准和潛在適應症方面的觀點。

調查方法：

這份Dapagliflozin市場報告主要基於DelveInsight內部資料庫、一手和二手研究以及產業專家團隊的內部分析所獲得的數據和資訊。二級資訊來源資訊和資料來自各種印刷和非印刷管道，例如搜尋引擎、新聞網站、全球監管機構網站、行業期刊、白皮書、雜誌、書籍、行業協會、行業入口網站以及對現有資料庫的存取。

DelveInsight提供的Dapagliflozin分析觀點

  • 對Dapagliflozin市場的詳細評估

這份Dapagliflozin銷售市場預測報告詳細評估了七大主要市場（美國、四個歐盟國家（德國、法國、義大利和西班牙）、英國和日本）中已通過核准的適應症（如重症肌無力）以及潛在適應症（如胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病、修格蘭氏症候群和全身性紅斑性狼瘡）的市場狀況。報告的這一部分提供了截至2034年的Dapagliflozin淨銷售現況及預測數據。

  • Dapagliflozin的臨床評價

這份Dapagliflozin市場報告提供了已通過核准和潛在適應症的臨床試驗資訊，包括研究干預措施、研究條件、實驗狀況、開始和完成日期。

Dapagliflozin的競爭格局

本報告深入分析了該領域的競爭對手和市售產品，並概述了新興產品及其預計上市日期，這些產品將在市場上造成激烈的競爭。

Dapagliflozin市場潛力及收入預測

  • Dapagliflozin淨的預期市場規模及其主要適應症
  • Dapagliflozin淨的預期銷售潛力（銷售尖峰時段預測）
  • Dapagliflozin淨定價策略和報銷情況

Dapagliflozin的競爭訊息

  • 在研競爭藥物數量（研發管線分析）
  • Dapagliflozin與現有療法相比的市場定位
  • Dapagliflozin相對於競爭對手的優勢與劣勢

Dapagliflozin淨監管與商業里程碑

  • Dapagliflozin的關鍵監管核准和預計上市時間
  • 商業合作、授權協議和併購活動

Dapagliflozin的臨床鑑別診斷

  • Dapagliflozin：與現有藥物相比，具有更優的療效和安全性
  • Dapagliflozin的獨特賣點

Dapagliflozin市場報告要點

  • 未來幾年，隨著達格列淨的廣泛應用、處方箋的增加以及在多種免疫適應症中的更廣泛應用，預計Dapagliflozin市場將發生變化，這將推動市場規模的成長。
  • Dapagliflozin相關企業正在開發以治療和改善疾病狀態的新方法為重點的治療方法，評估挑戰並探索可能影響Dapagliflozin優勢的機會。
  • 其他用於治療重症肌無力的新興產品，以及諸如胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病、修格蘭氏症候群和全身性紅斑性狼瘡等潛在適應症，預計將對Dapagliflozin淨構成激烈的市場競爭，而近期推出的後期治療方法預計也將對市場產生重大影響。
  • 它提供了Dapagliflozin在已通過核准和潛在適應症中的最新進展情況，並詳細說明了監管里程碑和研發活動。
  • 分析Dapagliflozin淨的成本、定價趨勢和市場定位，以支持免疫學領域的策略決策。
  • 我們對Dapagliflozin淨銷售預測數據到 2034 年的詳細分析將透過確定Dapagliflozin淨在已通過核准和潛在適應症中的整體情況，幫助您制定治療組合決策流程。

目錄

第1章 報告概述

第2章Dapagliflozin淨核准適應症概述，例如重症肌無力，以及潛在適應症，例如胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病、修格蘭氏症候群和全身性紅斑性狼瘡

  • 產品詳情
  • Dapagliflozin的臨床開發
    • Dapagliflozin的臨床試驗
    • Dapagliflozin臨床試驗資訊
    • 安全性和有效性
  • 其他發展活動
  • 產品簡介

第3章Dapagliflozin（非處方藥）的競爭格局

第4章 競爭格局（後期達格Dapagliflozin療法）

第5章Dapagliflozin市場評估

  • Dapagliflozin市場展望：已通過核准和潛在適應症
  • 對七個主要國家的分析
    • Dapagliflozin淨在七個主要國家已已通過核准和潛在適應症的市場規模
  • 各國市場
    • 美國Dapagliflozin市場規模（已通過核准適應症和潛在適應症）
    • 德國Dapagliflozin市場規模（已通過核准和潛在適應症）
    • Dapagliflozin淨在英國的市場規模（已通過核准和潛在適應症）

第6章Dapagliflozin的SWOT分析

第7章 分析師觀點

第8章附錄

第9章 DelveInsight 服務

第10章 免責聲明

第11章 關於 DelveInsight

第12章 報告購買選項

Product Code: DIDM1528

Key Factors Driving Dapagliflozin Growth

1. Market Share Gains and New Patient Starts

  • Dapagliflozin continues to gain market share across diabetes, heart failure, and chronic kidney disease (CKD) segments, driven by its broad cardiometabolic benefits.
  • Rising new patient initiations, particularly outside the traditional diabetes space, are supporting steady prescription and volume growth.
  • Strong physician familiarity and guideline-driven adoption are reinforcing its position as a foundational therapy in cardiology, nephrology, and endocrinology practices.

2. Expansion Across Key Indications

  • Type 2 Diabetes Mellitus (T2DM): Dapagliflozin remains a well-established SGLT2 inhibitor, offering durable glycemic control along with weight and blood pressure benefits.
  • Heart Failure (HFrEF and HFpEF): Rapid uptake as a standard-of-care therapy for heart failure regardless of diabetes status, supported by strong outcomes in reducing hospitalization and cardiovascular death.
  • Chronic Kidney Disease (CKD): Increasing use in CKD patients with and without diabetes, driven by demonstrated renal protection and slowed disease progression.
  • Ongoing research and lifecycle management continue to explore broader cardiometabolic and renal applications, reinforcing long-term market expansion.

3. Geographic Expansion

  • Dapagliflozin has achieved wide global penetration, with strong adoption across North America, Europe, and key emerging markets.
  • Asia-Pacific and Latin America are expected to witness accelerated growth due to rising diabetes prevalence, increasing diagnosis of heart failure and CKD, and improved access to innovative therapies.
  • Strategic pricing, local manufacturing, and partnerships are enabling deeper market reach in cost-sensitive regions.

4. New Indication Approvals

  • Multiple regulatory approvals across diabetes, heart failure, and CKD have significantly expanded Dapagliflozin's addressable patient population.
  • Label expansions beyond diabetes have repositioned the drug as a multispecialty therapy, strengthening its competitive profile against other glucose-lowering agents.
  • These approvals diversify revenue streams and reduce dependence on the diabetes-only market, enhancing long-term sustainability.

5. Strong Cardio-Renal Volume Momentum

  • Heart failure and CKD segments are major growth drivers, with sustained volume momentum driven by strong clinical outcomes and inclusion in international treatment guidelines.
  • Real-world and long-term follow-up data continue to reinforce confidence among cardiologists and nephrologists, accelerating uptake in newly diagnosed and high-risk patients.

6. Competitive Differentiation and Market Trends

  • Once-daily oral administration and a well-established safety profile provide convenience and support long-term adherence.
  • Disease-modifying benefits beyond glucose control differentiate Dapagliflozin from traditional antidiabetic therapies.
  • Alignment with broader healthcare trends, including integrated cardio-renal-metabolic care, early intervention, and value-based healthcare models, strongly supports continued adoption.
  • Growing real-world evidence (RWE) is strengthening payer acceptance and supporting favorable reimbursement decisions in multiple markets.

Dapagliflozin Recent Developments

Dapagliflozin have continued to emphasize its central role in cardio-renal-metabolic disease management. Updated clinical analyses and real-world studies have reinforced its benefits in heart failure across the ejection fraction spectrum and in CKD patients without diabetes, further expanding prescriber confidence. Ongoing post-marketing evidence and guideline updates have strengthened its positioning as a foundational therapy rather than an adjunct treatment. Additionally, continued inclusion in global and regional clinical practice guidelines has underscored its long-term relevance, while lifecycle management strategies focus on sustaining growth amid increasing competition within the SGLT2 inhibitor class.

"Dapagliflozin Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Dapagliflozin for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the 7MM. A detailed picture of Dapagliflozin's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Dapagliflozin for approved and potential indications. The Dapagliflozin market report provides insights about Dapagliflozin's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Dapagliflozin performance, future market assessments inclusive of the Dapagliflozin market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Dapagliflozin sales forecasts, along with factors driving its market.

Dapagliflozin Drug Summary

Dapagliflozin, marketed as Farxiga, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. By blocking SGLT2 in the proximal renal tubules, it prevents glucose reabsorption, promoting glycosuria, caloric loss, and blood glucose reduction independent of insulin, while also inducing natriuresis for blood pressure lowering and modest weight loss. Approved for oral once-daily dosing (5-10 mg), it offers cardioprotective and renoprotective benefits, reducing major adverse cardiovascular events, heart failure hospitalizations, and kidney disease progression across broad patient populations. The report provides Dapagliflozin's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Dapagliflozin is in the Phase III stage of clinical development for the treatment of patients with Type 2 Diabetes Mellitus (NCT04634500).

Scope of the Dapagliflozin Market Report

The report provides insights into:

  • A comprehensive product overview including the Dapagliflozin MoA, description, dosage and administration, research and development activities in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus.
  • Elaborated details on Dapagliflozin regulatory milestones and other development activities have been provided in Dapagliflozin market report.
  • The report also highlights Dapagliflozin's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
  • The Dapagliflozin market report also covers the patents information, generic entry and impact on cost cut.
  • The Dapagliflozin market report contains current and forecasted Dapagliflozin sales for approved and potential indications till 2034.
  • Comprehensive coverage of the late-stage emerging therapies for respective indications.
  • The Dapagliflozin market report also features the SWOT analysis with analyst views for Dapagliflozin in approved and potential indications.

Methodology:

The Dapagliflozin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dapagliflozin Analytical Perspective by DelveInsight

  • In-depth Dapagliflozin Market Assessment

This Dapagliflozin sales market forecast report provides a detailed market assessment of Dapagliflozin for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Dapagliflozin sales data uptil 2034.

  • Dapagliflozin Clinical Assessment

The Dapagliflozin market report provides the clinical trials information of Dapagliflozin for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Dapagliflozin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Dapagliflozin Market Potential & Revenue Forecast

  • Projected market size for the Dapagliflozin and its key indications
  • Estimated Dapagliflozin sales potential (Dapagliflozin peak sales forecasts)
  • Dapagliflozin Pricing strategies and reimbursement landscape

Dapagliflozin Competitive Intelligence

  • Number of competing drugs in development (pipeline analysis)
  • Dapagliflozin Market positioning compared to existing treatments
  • Dapagliflozin Strengths & weaknesses relative to competitors

Dapagliflozin Regulatory & Commercial Milestones

  • Dapagliflozin Key regulatory approvals & expected launch timelines
  • Commercial partnerships, licensing deals, and M&A activity

Dapagliflozin Clinical Differentiation

  • Dapagliflozin Efficacy & safety advantages over existing drugs
  • Dapagliflozin Unique selling points

Dapagliflozin Market Report Highlights

  • In the coming years, the Dapagliflozin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
  • The Dapagliflozin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Dapagliflozin's dominance.
  • Other emerging products for Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus are expected to give tough market competition to Dapagliflozin and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Dapagliflozin in approved and potential indications.
  • Analyse Dapagliflozin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
  • Our in-depth analysis of the forecasted Dapagliflozin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Dapagliflozin in approved and potential indications.

Key Questions:

  • What is the class of therapy, route of administration and mechanism of action of Dapagliflozin? How strong is Dapagliflozin's clinical and commercial performance?
  • What is Dapagliflozin's clinical trial status in each individual indications such as Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Dapagliflozin Manufacturers?
  • What are the key designations that have been granted to Dapagliflozin for approved and potential indications? How are they going to impact Dapagliflozin's penetration in various geographies?
  • What is the current and forecasted Dapagliflozin market scenario for approved and potential indications? What are the key assumptions behind the forecast?
  • What are the current and forecasted sales of Dapagliflozin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
  • What are the other emerging products available and how are these giving competition to Dapagliflozin for approved and potential indications?
  • Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
  • How cost-effective is Dapagliflozin? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Dapagliflozin Overview in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus

  • 2.1. Product Detail
  • 2.2. Dapagliflozin Clinical Development
    • 2.2.1. Dapagliflozin Clinical studies
    • 2.2.2. Dapagliflozin Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Dapagliflozin Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Dapagliflozin Therapies)

5. Dapagliflozin Market Assessment

  • 5.1. Dapagliflozin Market Outlook in approved and potential indications
  • 5.2. 7MM Analysis
    • 5.2.1. Dapagliflozin Market Size in the 7MM for approved and potential indications
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Dapagliflozin Market Size in the United States for approved and potential indications
    • 5.3.2. Dapagliflozin Market Size in Germany for approved and potential indications
    • 5.3.3. Dapagliflozin Market Size in France for approved and potential indications
    • 5.3.4. Dapagliflozin Market Size in Italy for approved and potential indications
    • 5.3.5. Dapagliflozin Market Size in Spain for approved and potential indications
    • 5.3.6. Dapagliflozin Market Size in the United Kingdom for approved and potential indications
    • 5.3.7. Dapagliflozin Market Size in Japan for approved and potential indications

6. Dapagliflozin SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

  • Table 1: Dapagliflozin, Clinical Trial Description, 2023
  • Table 2: Dapagliflozin, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: Dapagliflozin's pricing and cost Assumptions
  • Table 6: Dapagliflozin's Sales Analysis in the 7MM, in USD million (2020-2034)
  • Table 7: Dapagliflozin Market Size in the US, in USD million (2020-2034)
  • Table 8: Dapagliflozin Market Size in Germany, in USD million (2020-2034)
  • Table 9: Dapagliflozin Market Size in France, in USD million (2020-2034)
  • Table 10: Dapagliflozin Market Size in Italy, in USD million (2020-2034)
  • Table 11: Dapagliflozin Market Size in Spain, in USD million (2020-2034)
  • Table 12: Dapagliflozin Market Size in the UK, in USD million (2020-2034)
  • Table 13: Dapagliflozin Market Size in Japan, in USD million (2020-2034)

List of Figures

  • Figure 1: Dapagliflozin's Sales Analysis in the 7MM, USD million (2020-2034)
  • Figure 2: Dapagliflozin Market Size in the United States, USD million (2020-2034)
  • Figure 3: Dapagliflozin Market Size in Germany, USD million (2020-2034)
  • Figure 4: Dapagliflozin Market Size in France, USD million (2020-2034)
  • Figure 5: Dapagliflozin Market Size in Italy, USD million (2020-2034)
  • Figure 6: Dapagliflozin Market Size in Spain, USD million (2020-2034)
  • Figure 7: Dapagliflozin Market Size in the United Kingdom, USD million (2020-2034)
  • Figure 8: Dapagliflozin Market Size in Japan, USD million (2020-2034)